The payment period of contingent value rights under business combination.

No definition available.

Name:	chrs_BusinessCombinationConsiderationContingentValueRightPaymentPeriod
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percent of milestone and royalty based payments payable as part of contingent value rights under business combination.

+ References

No definition available.

+ Details

Name:	chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfMilestoneAndRoyaltyBasedPayments
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percent of upfront payments payable as part of contingent value rights under business combination.

+ References

No definition available.

+ Details

Name:	chrs_BusinessCombinationConsiderationContingentValueRightPaymentsPercentOfUpfrontPayments
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of contingent value rights issuable in consideration for each share under business combination.

+ References

No definition available.

+ Details

Name:	chrs_BusinessCombinationConsiderationContingentValueRightPerShare
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479405/805-10-25-23

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 8
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479637/805-30-30-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 7
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479637/805-30-30-7

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionAxis=chrs_SurfaceOncologyInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_SurfaceGlaxosmithklineAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_SurfaceNovartisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf114ProprietaryDrugProductAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_SurfaceSrf388ProprietaryDrugProductAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Surface Acquisition (Details) $ / shares in Units, $ in Millions		3 Months Ended
	Jun. 15, 2023 USD ($) Right $ / shares	Jun. 30, 2023 USD ($) $ / shares	Dec. 31, 2022 $ / shares
Surface Acquisition
Common stock, par value		$ 0.0001	$ 0.0001
Surface Oncology, Inc.
Surface Acquisition
Acquisition related costs \| $		$ 1.9
Scenario, Plan \| Surface Oncology, Inc.
Surface Acquisition
Common stock, par value	$ 0.0001
Value of shares issuable \| $	$ 40.0
Share price (in dollars per share)	$ 5.2831
Contingent value right per share \| Right	1
Contingent value rights payment period	10 years
Scenario, Plan \| Surface Oncology, Inc. \| Surface GSK Agreement
Surface Acquisition
Milestone and royalty based CVR payments (as percent)	70.00%
Scenario, Plan \| Surface Oncology, Inc. \| Surface Novartis Agreement
Surface Acquisition
Milestone and royalty based CVR payments (as percent)	70.00%
Scenario, Plan \| Surface Oncology, Inc. \| Surface's SRF114 proprietary drug product candidate
Surface Acquisition
Upfront payment based CVR payments (as percent)	25.00%
Scenario, Plan \| Surface Oncology, Inc. \| Surface's SRF388 proprietary drug product candidate
Surface Acquisition
Upfront payment based CVR payments (as percent)	50.00%